The risk of death according to left ventricular ejection fraction and right ventricular dilatation in 17&#x2009;321 adults with heart failure from 40 high-, middle- and low-income countries&#xa0;-&#xa0;A Global Congestive Heart Failure (G-CHF) study

Heart Failure

Heart failure with improved versus persistently reduced left ventricular ejection fraction: A comparison of the BIOSTAT-CHF (European) study with the ASIAN-HF registry

Eur J Heart Fail

Cao TH, Tay WT, Jones DJL, Cleland JGF, Tromp J, Emmens JE, Teng TK, Chandramouli C, Slingsby OC, Anker SD, Dickstein K, Filippatos G, Lang CC, Metra M, Ponikowski P, Samani NJ, Van Veldhuisen DJ, Zannad F, Anand IS, Lam CSP, Voors AA, Ng LL

doi: 10.1002/ejhf.3378

Heart Failure

Implementation of guideline-recommended therapies in heart failure with reduced ejection fraction according to heart failure duration: An analysis of 55 581 patients from the Swedish Heart Failure (SwedeHF) Registry

Eur J Heart Fail

Shahim A, Linde C, Savarese G, Dahlström U, Lund LH, Hage C

doi: 10.1002/ejhf.3565

Heart Failure

Treatment effects of empagliflozin in hospitalized heart failure patients across the range of left ventricular ejection fraction - Results from the EMPULSE trial

Eur J Heart Fail

Tromp J, Kosiborod MN, Angermann CE, Collins SP, Teerlink JR, Ponikowski P, Biegus J, Ferreira JP, Nassif ME, Psotka MA, Brueckmann M, Blatchford JP, Steubl D, Voors AA

doi: 10.1002/ejhf.3218

Heart Failure

Cause-specific death in heart failure across the ejection fraction spectrum: A comprehensive assessment of over 100 000 patients in the Swedish Heart Failure Registry

Eur J Heart Fail

Settergren C, Benson L, Shahim A, Dahlström U, Thorvaldsen T, Savarese G, Lund LH, Shahim B

doi: 10.1002/ejhf.3230

Heart Failure

Heart failure in Europe: Guideline-directed medical therapy use and decision making in chronic and acute, pre-existing and de novo, heart failure with reduced, mildly reduced, and preserved ejection fraction - the ESC EORP Heart Failure III Registry

Eur J Heart Fail

Lund LH, Crespo-Leiro MG, Laroche C, Zaliaduonyte D, Saad AM, Fonseca C, Čelutkienė J, Zdravkovic M, Bielecka-Dabrowa AM, Agostoni P, Xuereb RG, Neronova KV, Lelonek M, Cavusoglu Y, Gellen B, Abdelhamid M, Hammoudi N, Anker SD, Chioncel O, Filippatos G, Lainscak M, McDonagh TA, Mebazaa A, Piepoli M, Ruschitzka F, Seferović PM, Savarese G, Metra M, Rosano GMC, Maggioni AP, ESC EORP HF III National Leaders and Investigators

doi: 10.1002/ejhf.3445

Heart FailureMyocardial Infarction

Left Ventricular Function, Congestion, and Effect of Empagliflozin on Heart Failure Risk After Myocardial Infarction

J Am Coll Cardiol

Udell JA, Petrie MC, Jones WS, Anker SD, Harrington J, Mattheus M, Seide S, Amir O, Bahit MC, Bauersachs J, Bayes-Genis A, Chen Y, Chopra VK, Figtree G, Ge J, Goodman SG, Gotcheva N, Goto S, Gasior T, Jamal W, Januzzi JL, Jeong MH, Lopatin Y, Lopes RD, Merkely B, Martinez-Traba M, Parikh PB, Parkhomenko A, Ponikowski P, Rossello X, Schou M, Simic D, Steg PG, Szachniewicz J, van der Meer P, Vinereanu D, Zieroth S, Brueckmann M, Sumin M, Bhatt DL, Hernandez AF, Butler J

doi: 10.1016/j.jacc.2024.03.405

Heart Failure

Investigation of left ventricular ejection fraction in a Swiss heart failure population: Insights into mortality and sex differences

ESC Heart Fail

Fuentes Artiles R, Meçani R, Muka T, Hunziker L, Capék L

doi: 10.1002/ehf2.15174

Heart Failure

Cardiac rhythm devices in heart failure with reduced ejection fraction - role, timing, and optimal use in contemporary practice. European Journal of Heart Failure expert consensus document

Eur J Heart Fail

Bozkurt B, Mullens W, Leclercq C, Russo AM, Savarese G, Böhm M, Hill L, Kinugawa K, Sato N, Abraham WT, Bayes-Genis A, Mebazaa A, Rosano GMC, Zieroth S, Linde C, Butler J

doi: 10.1002/ejhf.3641

Heart Failure

Use of medical therapy and risk of clinical events according to frailty in heart failure patients - A real-life cohort study

Eur J Heart Fail

Zahir Anjum D, Strange JE, Fosbøl E, Garred CH, Elmegaard M, Andersson C, Jhund PS, McMurray JJV, Petrie MC, Kober L, Schou M

doi: 10.1002/ejhf.3249

Cardiovascular

The risk of death according to left ventricular ejection fraction and right ventricular dilatation in 17 321 adults with heart failure from 40 high-, middle- and low-income countries - A Global Congestive Heart Failure (G-CHF) study

Related content

Heart failure with improved versus persistently reduced left ventricular ejection fraction: A comparison of the BIOSTAT-CHF (European) study with the ASIAN-HF registry

Implementation of guideline-recommended therapies in heart failure with reduced ejection fraction according to heart failure duration: An analysis of 55 581 patients from the Swedish Heart Failure (SwedeHF) Registry

Treatment effects of empagliflozin in hospitalized heart failure patients across the range of left ventricular ejection fraction - Results from the EMPULSE trial

Cause-specific death in heart failure across the ejection fraction spectrum: A comprehensive assessment of over 100 000 patients in the Swedish Heart Failure Registry

Heart failure in Europe: Guideline-directed medical therapy use and decision making in chronic and acute, pre-existing and de novo, heart failure with reduced, mildly reduced, and preserved ejection fraction - the ESC EORP Heart Failure III Registry

Left Ventricular Function, Congestion, and Effect of Empagliflozin on Heart Failure Risk After Myocardial Infarction

Investigation of left ventricular ejection fraction in a Swiss heart failure population: Insights into mortality and sex differences

Cardiac rhythm devices in heart failure with reduced ejection fraction - role, timing, and optimal use in contemporary practice. European Journal of Heart Failure expert consensus document

Use of medical therapy and risk of clinical events according to frailty in heart failure patients - A real-life cohort study